What is type 2 diabetes?
Type 2 diabetes is a chronic metabolic condition characterised by elevated blood glucose due to a combination of insulin resistance (reduced cellular response to insulin) and progressive beta-cell dysfunction (reduced pancreatic insulin secretion capacity). The principal approved clinical indication for semaglutide and tirzepatide.
What the research literature says
Type 2 diabetes accounts for roughly 90-95% of diabetes cases globally. The condition typically develops over years through progressive insulin resistance (in adipose, hepatic, and muscle tissue) combined with declining pancreatic beta-cell function. The natural history runs from normal glucose tolerance through impaired glucose tolerance (pre-diabetes) to overt type 2 diabetes; the progression is associated with obesity, inactivity, and genetic predisposition.
Modern incretin-receptor agonists provide a pharmacological framework that addresses both arms of the underlying pathophysiology — restoring incretin-effect-mediated insulin secretion and producing weight reduction that improves underlying insulin resistance. The SUSTAIN program characterised semaglutide’s type 2 diabetes efficacy (PMID 28110911 SUSTAIN-1; PMID 27633186 cardiovascular outcomes; PMID 30615985 cross-program analysis). The SURPASS program characterised tirzepatide’s efficacy in the same context (PMID 34170647 head-to-head against semaglutide; PMID 34672967 vs insulin glargine).
The Thomas tirzepatide beta-cell-function-and-insulin-sensitivity work characterised the mechanism arms relevant to the underlying type 2 diabetes pathophysiology (PMID 33236115). Both compound classes (single and dual receptor agonists) are FDA-approved for type 2 diabetes management.
Why this matters in research context
Type 2 diabetes matters in peptide-research contexts as the principal clinical indication anchoring the long-acting incretin-receptor-agonist development programs. Researchers studying semaglutide or tirzepatide should understand the underlying pathophysiology — the dual-arm framework (insulin resistance + beta-cell dysfunction) shapes both the clinical endpoints and the experimental measurements that anchor research protocols.
Related compounds
- Semaglutide 10mg — FDA-approved for type 2 diabetes
- Tirzepatide 10mg — FDA-approved for type 2 diabetes
Related research questions
References
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016;375(19):1834-1844. [PMID 27633186]
- Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol 2017;5(4):251-260. [PMID 28110911]
- Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab 2021;106(2):388-396. [PMID 33236115]
- Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385(6):503-515. [PMID 34170647]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.